Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Equity Average: 2011-2017

Historic Equity Average for Tenax Therapeutics (TENX) over the last 2 years, with Sep 2017 value amounting to $10.7 million.

  • Tenax Therapeutics' Equity Average fell 78.04% to $10.7 million in Q3 2017 from the same period last year, while for Sep 2017 it was $10.7 million, marking a year-over-year decrease of 78.04%. This contributed to the annual value of $43.8 million for FY2016, which is N/A change from last year.
  • Tenax Therapeutics' Equity Average amounted to $10.7 million in Q3 2017, which was down 15.56% from $12.7 million recorded in Q2 2017.
  • Tenax Therapeutics' Equity Average's 5-year high stood at $48.8 million during Q3 2016, with a 5-year trough of -$1.7 million in Q2 2013.
  • For the 2-year period, Tenax Therapeutics' Equity Average averaged around $23.9 million, with its median value being $15.6 million (2017).
  • Examining YoY changes over the last 5 years, Tenax Therapeutics' Equity Average showed a top increase of 63.92% in 2013 and a maximum decrease of 177.50% in 2013.
  • Quarterly analysis of 3 years shows Tenax Therapeutics' Equity Average stood at -$1.7 million in 2013, then reached $31.9 million in 2016, then slumped by 78.04% to $10.7 million in 2017.
  • Its Equity Average stands at $10.7 million for Q3 2017, versus $12.7 million for Q2 2017 and $15.6 million for Q1 2017.